Expansion Opportunities MilliporeSigma is actively expanding its European and US facilities, including a €25 million BioReliance testing facility in Darmstadt and a $29 million biologics testing facility in Germany, signaling increased capacity for contract testing and drug substance/product release services that sales teams can target with expanded service contracts and new modality support.

Bioconjugation Growth A major $76 million expansion of the Bioconjugation Center of Excellence in St. Louis highlights ongoing investments in advanced bioconjugation capabilities, presenting a window to upsell specialized reagents, analytical services, and collaborative development programs for biotech and pharma customers focusing on conjugation-enabled therapies.

Strategic Talent Leadership appointments in discovery, strategy and development indicate a strategic push to accelerate innovation and solution delivery, offering opportunities to engage potential customers around integrated discovery solutions, platform tooling, and customized service offerings for early-stage to late-stage development programs.

Sustainability Positioning Active participation in sustainability leadership, including keynote engagement at CHEMUK 2026, provides a platform to position MilliporeSigma as a partner for sustainable lab workflows, green chemistry initiatives and digital offerings that appeal to customers prioritizing ESG-aligned procurement.

Integrated CDMO Services The portfolio emphasizes best-in-class pharmaceutical development and manufacturing tools with a fully integrated service organization for CDMO and contract testing across traditional and novel modalities, presenting cross-sell opportunities to pharma and biotech firms seeking a one-stop partner for development, testing and manufacturing support.